Advertisement


William G. Wierda, MD, PhD, on CLL/SLL: Updated Findings on Ibrutinib and Venetoclax

2024 ASCO Annual Meeting

Advertisement

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses up to 5.5 years of follow-up data from the phase II CAPTIVATE study, showing that in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), fixed duration ibrutinib plus venetoclax continues to provide clinically meaningful progression-free disease in those with high-risk genomic features as well as in the overall population (Abstract 7009).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
This year I presented an update of the CAPTIVATE study, which is a multi-center study, an international study, actually, of a combined targeted therapy for patients with chronic lymphocytic leukemia who were previously untreated. The treatment was for three months of ibrutinib monotherapy, followed by 12 months or 12 cycles of combined therapy, ibrutinib plus venetoclax. There were two cohorts in this study. We focused, in this presentation, on the fixed-duration cohort. So all the patients received the 12 cycles of combined therapy and then stopped treatment for follow-up. And this was a five-and-a-half-year update of these data. We've presented these data previously with earlier data cuts, but the overall summary of and important points that were presented at ASCO this year was we focused on patients with high-risk features. Those were patients who had 17p deletion or mutated TP53 or a complex karyotype. And we reported the outcomes for that subgroup of patients compared to individuals who didn't have those high-risk features. We saw a lower five-year progression-free survival rate for patients with high-risk features. We also saw a lower five-year progression-free survival rate for patients with an unmutated immunoglobulin gene compared to those who have a mutated immunoglobulin gene. But overall, we did not identify, or we could not estimate, the median progression-free survival for the whole group or for the subgroups. So these patients are doing exceptionally well with a median that extends beyond a five-year follow-up, which illustrates to us that it is a reasonable option to recommend for patients, even with a high-risk feature, this fixed duration treatment with combined targeted therapy. Again, this is an all-oral regimen. It did not include a CD20 antibody, and we saw very high undetectable MRD rates, which correlated with long progression-free survival. This trial, again, has been previously presented. This was a follow-up and longer follow-up data available. It has been an important regimen. It is approved in the European Union. It's not approved in the U.S., but we do have it on the NCCN guidelines. So it is a treatment option for our patients. One of the questions has been what is the optimal patient population for this regimen? My opinion is that patients who do very well with this regimen are patients who have an unmutated immunoglobulin gene, their MRD rates, undetectable MRD rate, is higher than patients with a mutated immunoglobulin gene, and it's a very well-tolerated combination for our patients. And so I think of this regimen when I have a patient who is younger than 70 and has an unmutated immunoglobulin gene as an ideal first-line treatment option for that patient population.

Related Videos

Lymphoma

Yasmin H. Karimi, MD, on Large B-Cell Lymphoma: Follow-up on Subcutaneous Epcoritamab Monotherapy

Yasmin H. Karimi, MD, of the University of Michigan Comprehensive Cancer Center, discusses 2.5-year follow-up data on epcoritamab monotherapy for patients with relapsed or refractory large B-cell lymphoma. The subcutaneous regimen continues to demonstrate durable responses (Abstract 7039).

Multiple Myeloma

Xavier P. Leleu, MD, PhD, on Multiple Myeloma: Update on Isatuximab, Lenalidomide, Dexamethasone, and Bortezomib

Xavier P. Leleu, MD, PhD, of France’s Université de Poitiers and Centre Hospitalier Universitaire de Poitiers, discusses phase III findings showing that isatuximab in combination with bortezomib, lenalidomide, and dexamethasone deepened responses and increased the rate of measurable residual disease negativity vs isatuximab with lenalidomide and dexamethasone in patients with newly diagnosed transplant-ineligible multiple myeloma (Abstract 7501).

Gynecologic Cancers

Jean-Marc Classe, MD, PhD, on Ovarian Cancer: New Data on Lymphadenectomy From the CARACO Trial

Jean-Marc Classe, MD, PhD, of France’s Nantes Université, discusses phase III results showing that systematic lymphadenectomy should be omitted in patients with advanced epithelial ovarian cancer with clinically negative lymph nodes, as well as those undergoing neoadjuvant chemotherapy and interval complete surgery (LBA5505).

Lung Cancer

Minesh P. Mehta, MD, on NSCLC: Tumor Treating Fields for Brain Metastases

Minesh P. Mehta, MD, of Miami Cancer Institute, part of Baptist Health South Florida, discusses results from the METIS (EF-25) trial evaluating the efficacy and safety of tumor treating fields therapy following stereotactic radiosurgery in patients with mutation-negative non–small cell lung cancer (NSCLC) and brain metastases. Tumor treating fields therapy prolongs time to intracranial disease progression and may postpone whole-brain radiation therapy without declines in quality of life and cognition (Abstract 2008).

Multiple Myeloma

Paula Rodríguez-Otero, MD, PhD, and Amrita Y. Krishnan, MD, on Multiple Myeloma: Moving BCMA-Directed Therapies to Earlier Use

Paula Rodríguez-Otero, MD, PhD, of Spain’s Cancer Center Clínica Universidad de Navarra, and Amrita Y. Krishnan, MD, of the City of Hope Cancer Center, discuss two key studies on B-cell maturation antigen (BCMA)-directed therapies: CARTITUDE-4 on ciltacabtagene autoleucel in patients with functional high-risk multiple myeloma; and DREAMM-7 on belantamab mafodotin-blmf plus bortezomib and dexamethasone vs daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory disease.

Advertisement

Advertisement




Advertisement